BioAgilytix offers Enzyme-Linked ImmunoSpot (ELISPOT) assays at our European laboratory in Hamburg, Germany. We use ELISPOT to visualize the secretory product(s) of individual activated or responding cells to analyze the frequencies of rare antigen-specific cells within a test population, such as single positive cells within a population of peripheral blood mononuclear cells (PBMCs).
Learn More About the ELISPOT Platform:
BioAgilytix’s experts are here to help. Let’s schedule a conversation to review your questions and requirements with one of our scientists.
ELISPOT assays employ the sandwich enzyme-linked immunosorbent assay (ELISA) technique, where either a monoclonal or polyclonal antibody specific for the chosen analyte is pre-coated onto a PVDF (polyvinylidene difluoride)-backed microplate. Freshly isolated, thawed, or cultured cells are plated together with the antigens of interest and incubated to allow for the activation of the antigen-specific T cells and the induction of their cytokine secretion.
As the antigen-specific cells are activated, they release the cytokine, which is captured directly on the membrane surface by the immobilized antibody. The visualization of the cytokines secreted individual T- or B-clones is achieved by enzyme-conjugated or fluorescence-based substrates. The fluorescence-based method allows a multiplex analysis of antigen-specific clones. The spots are then counted with the automated ELISPOT reader system.
The ELISPOT platform is considered among the most useful for determining cell-mediated immunity because of its sensitivity and specificity in detecting rare antigen-specific T cells (or B cells). ELISPOT assays are able to provide qualitative information regarding the specific cytokine or other secreted immune molecule.
At BioAgilytix, we most frequently utilize ELISPOT in our work with immunogenicity testing, immune response monitoring, epitope discovery, and helper T cell response evaluation. We can also use fluorescently labeled antibodies, even in parallel via multiplexing.
Platform In Action:
Learn why the European Immunogenicity Platform (EIP) believes that a multidisciplinary approach is warranted to better understand and minimize drug immunogenicity.
With ELISPOT, our scientific team is able to achieve the degree of sensitivity needed to accurately detect and enumerate rare antigen-specific cells and evaluate helper T cell response. We’ve proven our expert ability to leverage this platform to deliver high-quality qualitative results.
Speak with one of our ELISPOT experts about your scientific requirements, and we will discuss how the features of this platform can be optimally applied your assay requirements.